Dr. Al-Kadhimi's primary research interest is in transplant immunology and applications to use both autologous and allogeneic transplants as platforms for cellular therapy and cancer immunotherapy.
Titles and Roles
- Associate Professor, Department of Hematology and Medical Oncology
- Emory University School of Medicine
- Research Program
- Discovery and Developmental Therapeutics
Zaid Al-Kadhimi, MD, joined the Bone Marrow and Stem Cell Transplant Center team at Winship Cancer Institute in 2014. He previously worked at the Karmanos Cancer Institute at Wayne State University in the Bone Marrow Transplant and Immunotherapy program.
Dr. Al-Kadhimi earned his medical degree from the University of Baghdad Medical School in 1991. In 1997, he completed his residency in internal medicine at Henry Ford Hospital in Detroit, Michigan. Dr. Al-Kadhimi then went on to complete his fellowship at City of Hope, University of California at Los Angeles in blood cancer and bone marrow transplant.
Recent awards for Dr. Al-Kadhimi include:
- Mentored Clinical Scientist Development Program Award (K12 Award), 2004-2007, Lymphoma Research Foundation Fellowship Award
- Amgen Hematology/Stem Cell Transplantation Award, 2001/2002
- Lymphoma Research Foundation Fellowship Award
- Depletion of immune suppressor cells from autologous graft with the goal of improving immune reconstitution and anti-tumor immune response post-transplant. In a small investigator initiated trial with immune correlative studies (day 15 lymphocyte/ monocyte recovery and phenotype), which can be compared with base line. Preliminary data can be used for a R21 proposal. Such trial has a potential of changing the paradigm of autologous transplant.
- Prevention of GVHD both acute and chronic post unrelated transplants (From HLA 8/8 and 7/8 matched donors). Based on encouraging results we observed in reducing GVHD rates with triple immune suppression strategy, I hope to further develop this regimen to reduce non relapse mortality (NRM) at 1 and 5 years post-transplant. Reducing NRM without increasing relapse can improve overall transplant outcomes. Furthermore, this strategy can be well complemented with low dose DLI post-transplant to further prevent relapse.
- Develop haploidentical transplant. I will focus on having a transplant platform of: enriched donor innate immune cells, enriched host homeostatic cytokines, and depleted donor adaptive immune cells early post-transplant. Such a platform will allow for in vivodonor innate cell activating interventions with the goal of generating allo reactive innate immune response (GVL) without GVHD.